The National Kidney Foundation (NKF) is honoring Relypsa, Inc. with its first-ever Corporate Innovator Award in recognition of the biopharmaceutical company's breakthrough development of Veltassa, the first new hyperkalemia (high-potassium) treatment medicine approved by the FDA in over 50 years. This new drug will offer an additional treatment option for patients with kidney failure who have high potassium levels.
The National Kidney Foundation believes that having more choices for managing underlying conditions related to kidney disease (secondary hyperparathyroidism, anemia, etc.) is better for doctors and patients. "NKF has traditionally recognized individuals for research, education, and service to the kidney health community, but there are also organizations in the business sector that drive change," said NKF CEO Kevin Longino. "This award acknowledges Relypsa's important contributions toward improving treatment and care of people with kidney disease."
"It is a great honor to have been selected to receive the NKF's first Corporate Innovator Award," said Lance Berman, M.D., chief medical officer of Relypsa. "We focus our efforts on improving the lives of people with hyperkalemia, and we are especially proud to be recognized by the very foundation which represents so many of these patients."
The award will be presented to Dr. Berman at the NKF 2016 Spring Clinical Meetings, the Foundation's annual kidney treatment educational convention, taking place in Boston April 27-May 1.
Hyperkalemia is common among people receiving kidney dialysis and people taking certain medications for kidney disease. Normal levels of potassium are needed for the functioning of the heart, nerves, and muscles. High levels of potassium can lead to heart rhythm problems that can be fatal. Healthy kidneys normally filter out extra potassium from the body. In patients with elevated potassium levels, clinical trials have shown Veltassa binds to potassium in exchange for calcium , etc.
Think about it Lurker, what about ZS-9 says "approval" w/o any concerns??? The FDA is not going to ignore the trials (long term) questions and the latest issue on AIN concerns.
Reflects (Wainwright/ARCE) the BIO downturn too (the IBB/XBI). Valuation has changed (new rules by ????) while the future sales of approved products are mostly maintained.
Yep, Jimmymac and DUMBrunner are twin sons of different mothers. Pound any of us into depression and to question any DD that might have been. Nevermind the significant collabpse of the BIO indexes that have MANY stocks valued at bext 75% of what they were. Some are still down 35-40% since last August while the S&P and DOW are closer to full recovery.
in Alabama (been awhile) responding to questions of "results after use" and BP impact:
Rajesh Boorgu ?@rboorgu1 � 14h14 hours ago
$rlyp Another one. K+improve from 6.2 to 5.0 BP improved from 170/93 to 125/65 after titrating up losartan it works
Rajesh Boorgu ?@rboorgu1 � 20h20 hours ago
@WhiteCoatMafia Veltassa started on 8.4g 1 mo #$%$ potassium improved 6.4 to 4.7 BP improved 151/74 to 135/65
Only two examples but fits the profile of what we were to expect - good news either way
OK but if they were going to do a SO, last week would have been the time for about $21/shr for 10-15M shares and maybe the PPS drops to $17-$18 but climbs having that ISSUE out of the way for 2 years. They are not going to wait until the PPS drops to $15 to so an SO - THAT would be STUPID (similar to AZN paying $2.7B). GL
Below is the side effect profile for ZS-9 (overload of Sodium!!).
Adverse Event (AE) % N
Any event 51.6 353
All Peripheral Edema 7.7 53
Edema requiring treatment 4.2 29
Hypertension 7.0 48
Hypokalemia (Serum K+ = 3.0 to 3.5 mEq/L) 2.5 17
Hypokalemia (Serum K+
They were acquired because ALL the other interested bidders passed on not knowing the ZS005 interim trials result and MORE importantly not having an escape clause if ZS-9 does not get a clean approval. BUT, they are all DUMB and AZN is the smartest? Quit it MAC because you sound more foolish every post. Sorry I drew you out. By te way, what you also are implying is ORBIMED and JANUS are STUPID buying a good amount of RLYP and not selling everything last December.
$11 not $15? your posts are back to foolishness. ZS-9 CLEAN label? You drinking already? Please explain why their LT trials have no data other than ;last November's very concerning interim data on 63 patients? you think ZS-9 will be SOC for Acute and Chronic?
Bull, the IBB and XBI are still down 30% off highs when RLYP was about $30/shr. YOU said this stock would never see $20 again back in Jan-Feb. How do you really think ZS-9 is a superior drug (Berens?)? You got your "lucky lotto" money with ZSPH's buyout. You probably are short here so cover and move on. (agree that CASH is an issue in the next 3 months though)
There were 3 separate 80K BUYS yesterday separated by a few hours. That must have been US guys (retail fools) buying those shares. And Thursday's volume was US guys buying 6M shares on a "rumor" that has no substance.
so YOU are rumrunner - I mean DUMBrunner - I thought my post would draw you out jimmy - too funny LOL
$56 or $58 - whatever it takes. This latest announcement of Veltassa progress beyond CHK AND Relypsa's partnership with the national Kidney foundation are supporting more value.
Lurker, $58 is ONLY about $2.5B. How does that not make sense? Why would you value Relypsa only at $1.3B or thereabouts? The BOD and the Big Tutes ownership will not accept $28-$30/shr only. That's a lawsuit of epic proportions. Anything above $40/shr could pass muster. Are you also saying that ZS-9 is now getting approval in May like Pharma predicts????? No freakin' way
Valuations have been creeping back up though still off by 30% etc. Big Pharma has reached the point where their "patents" are running out allowing generics into the market. Veltassa has extended patents for the next (12 yrs??) plus a viable drug/market AND it is APPROVED. Now that the Pfizer $160B takeover has been scratched (Allergan?) and hardly any M&As have occurred in the last months, something has to happen (due to cash on hand at Big Pharma) IMO.
Merck is just over $56 Lurker (not $81). go read MRK market pulse backwards into mid-day Thursday. Yes, I agree, no substantiation but this one seems more palatable. I dismissed the $3.3B rumor FWIW. I am not spreading this other than to point to a discussion that was going on during Thursday's run up. Yesterday's action with RLYP was very encouraging with the dismal beat down most of the day with NASDAQ and the BIO indexes. We held our ground.
It was part of the twitter discussion/rumor on Thursday. I saw it referenced on the MRK market pulse "discussion".
That is my understanding too. Must keep track of both your cost basis though (make believe $28 is .5 for MRK and $15 for RLYP). So, if you sold MRK at ANY price after (whether it be $30 or $25) that would have to be calculated against what your COST basis was when you bought RLYP. It gets a bit harry but you will not have to pay any tax until actual sale of MRK. ALL IMHO.